An observational study in HIV, Reproductive Health and Disability, sponsored by ANRS, Emerging Infectious Diseases. Completed at 1 site in Cameroon. Open to participants aged 15 Years to 49 Years. Per ClinicalTrials.gov, last updated 2016-07-12.
Sponsored by ANRS, Emerging Infectious Diseases · Observational
According to the recent World Report on Disability, around 15% of the world population lives with a disability and 80% of people with disabilities (PWD) live in developing countries. More and more evidence show that PWD are more likely to be poor, vulnerable to physical and sexual violence, and to have less access to education. Therefore, PWD are likely to have an increased risk for HIV infection, potentially being a key population in regard to this epidemic.
The vulnerability of PWD was recognized in 2007 by the United Nations Convention on the Rights of Persons with Disabilities. However, data on the extent how PWD are affected by HIV is still very limited. As a result, PWD are usually overlooked by National AIDS Control Programmes and few projects specifically targeting them have been developed.
Recognizing the need for appropriate and reliable data to help protect the rights of PWD and achieve a better inclusion of disability in National AIDS Control Programmes, the Institute of Research for Development (IRD), the Institut de Formation et Recherche Demographique (IFORD) and Handicap International (HI) propose this study that aims to provide quantitative and qualitative data on the vulnerability of PWD to HIV infection in Cameroon and Burkina Faso, in order to define if this vulnerable population is also a Key Population in relation to the HIV epidemic. This study adopts a multidisciplinary approach (quantitative and qualitative methods). Quantitative data are collected only in Cameroon.
Only the quantitative study is described here.
OBJECTIVES:
The general objective of this study is to provide information on the vulnerability of PWD to HIV infection.
The objectives of the quantitative component of this study are:
Estimation of the HIV burden among PWD:
Assessment of the knowledge, behaviour and practice toward HIV infection and sexual and reproductive health (including contraception) overall and for each of the impairment groups mentioned above:
Access to HIV prevention and health careglobally and for each of the impairment groups mentioned above:
Specific objectives related to disability:
METHODOLOGY
Study design:
This is a cross sectionnal study assessing HIV prevalence, HIV risk factors and sexual \& reproductive health of PWD compared to a control group of Non-Disabled People. PWD are sampled from the general population using a two-step sampling method. Eligible subjects are proposed an HIV test and to respond to a questionnaire on their Knowledge, Attitudes and Practices (KAP) in relation to HIV and SRH, on their social network and on their access to prevention and care services. The life-grid interview method is used to collect data on subject's history of social participation, employment, resources, sexual partnership and reproductive life. Controls are selected from the PWD's neighborhood.
Sample size:
850 disabled subjects and 850 non-disabled controls
Study location: Yaounde, Cameroon
Estimated planning or Study timetable :
Study start date: April 2014 (exploratory work) Total trial/study duration: 24 months
4,258 studies on the registry are indexed under HIV Infections; 240 are open to participants now.
This study's enrollment of 1,610 is above the median of 200 across 713 observational studies indexed under HIV Infections.
Browse HIV Infections studies →ANRS, Emerging Infectious Diseases is the lead sponsor of 212 studies on the registry; 40 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Community sample:
A stratified cluster sampling in 2 steps is used in Yaounde. The city has been divided in enumeration areas (EAs). First step : EAs are drawn randomly with probability proportional to their size in number of households. Second step: in each EA, 30 households are randomly drawn and each person living in these households is screened for disability with the WG tool, according to the inclusion and exclusion criteria.
For PWD:
Inclusion Criteria:
Exclusion Criteria:
For Non-Disabled People (control group):
Inclusion criteria:
Exclusion criteria:
PWD will be identified thanks to the disability screening tool developped by the Washington Group (WG). This tool is based on the WHO International Classification of Functionning (ICF). A stratified cluster sampling in 2 steps will be used in both, Yaounde and Ouagadougou. Each city will be divided in enumeration areas (EAs). First step : EAs will be drawn randomly with probability proportional to their size in number of households. Second step: in each EA, 30 households will be randomly drawn and each person living in these households will be screened for disability with the WG tool, according to the inclusion and exclusion criteria.
For each PWD, 1 non-disabled control person will be randomly chosen from the census list of the same enumeration area. Control will also be matched on age and sex.
HIV prevalence
HIV prevalence among People With Disability compared to Non-Disabled People. HIV serology will be assessed by rapid diagnostic tests.
Time frame: 10 months
Risk factors
Risk factors to HIV and reproductive health behaviours among People with Disability compared to Non-Disabled People. Different risk factors (Knowledges - Attitudes - Practices) for HIV and reproductive health behaviours will be assessed in both groups, the people with disability group and the control non-disabled people group, through a questionnaire.
Time frame: 10 months
Access to care
Access to services among People with Disability compared to Non-Disabled People. Access to reproductive health and HIV services will be assessed in both groups, through a questionnaire.
Time frame: 10 months
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ANRS, Emerging Infectious Diseases